ChemoCentryx is a biopharmaceutical company focused on the development of medications targeting inflammatory disorders, autoimmune diseases and cancer. Each of Co.'s drug candidates is designed to selectively block a specific chemoattractant receptor. Co. is preparing for a potential commercial launch of avacopan for the treatment of patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Co. is also developing avacopan for the treatment of severe (Hurley Stage III) hidradenitis suppurativa. CCX559 is Co.'s orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1, which Co. is developing for the treatment of various cancers.